4Folkman J. Role of angiogenesis in tumor growth and metastasis.Semin Oncol,2002,29(6 Suppl 16) : 15-18.
5Huang X, Wong MK, Zhao Q, et al. Soluble recombinant endostatinpurified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res,2001,61(2): 478-481. Erratum in:Cancer Res, 2001,61 ( 15 ) : 5956. Cancer Res, 2001,61 (10) :4297.
6Li B, Wu XY, Zhou H, et al. Acid-induced unfolding mechanism of recombinant human endostatin. Biochemistry, 2004, 43 (9) :2550-2557.
7Eder JP Jr, Supko JG, Clark JW, et al. Phase Ⅰ clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol, 2002,20(18) : 3772-3784.
8Kulke M, Bergsland E, Ryan DP, et al. A phase Ⅱ , open-label,safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc ASCO,2003,22: 958a.
9Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced nonsmall cell lung cancer. J Clin Oncol,2002,20(21) : 4285-4291.
10Gebbia V, Galetta D, Caruso M, et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine fol lowed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage Ⅲ B-Ⅳ non small cell lung carcinoma: a prospective randomized phase Ⅲ trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer,2003,39(2) :179-189.
